卵清蛋白
载脂蛋白B
霍乱毒素
免疫系统
免疫学
化学
融合蛋白
鼻腔给药
分子生物学
内分泌学
生物
胆固醇
生物化学
重组DNA
基因
作者
Roland Klingenberg,Michael Lebens,Andreas Hermansson,Gunilla Nordin Fredrikson,Daniela Strodthoff,Mats J. Rudling,Daniel F.J. Ketelhuth,Norbert Gerdes,Jan R. Holmgren,Jan Åke Nilsson,Göran K. Hansson
标识
DOI:10.1161/atvbaha.109.202671
摘要
OBJECTIVE: Atherosclerosis is an inflammatory disease. Autoimmune responses to low-density lipoproteins (LDL) contribute to its progression, whereas immunization with LDL may induce atheroprotective or proatherogenic responses. The objective of this study was to develop an atheroprotective vaccine by targeting a peptide of the LDL protein constituent apolipoprotein B-100 (apoB-100) to the nasal mucosa to induce a protective mucosal immune response. METHODS AND RESULTS: A peptide comprising amino acids 3136 to 3155 of apoB-100 (p210) was fused to the B subunit of cholera toxin (CTB), which binds to a ganglioside on mucosal epithelia. The effect of nasal administration of the p210-CTB fusion protein on atherogenesis was compared with that of an ovalbumin peptide fused to CTB and with untreated controls. Immunization with p210-CTB for 12 weeks caused a 35% reduction in aortic lesion size in Apoe(-/-) mice. This effect was accompanied by induction of regulatory T cells that markedly suppressed effector T cells rechallenged with apoB-100 and increased numbers of interleukin (IL)-10(+) CD4(+) T cells. Furthermore, a peptide-specific antibody response was observed. Atheroprotection was also documented in apoe(-/-) mice lacking functional transforming growth factor-beta receptors on T cells. CONCLUSION: Nasal administration of an apoB-100 peptide fused to CTB attenuates atherosclerosis and induces regulatory Tr1 cells that inhibit T effector responses to apoB-100.
科研通智能强力驱动
Strongly Powered by AbleSci AI